Adaptimmune Therapeutics PLC SEC filings ADAPY
Adaptimmune Therapeutics PLC has 808 filings in SEC EDGAR's recent list, going back to Oct 2, 2014. Its latest annual report, Form ARS, was filed on Apr 25, 2025 for the period ended Dec 31, 2024. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2025, covering the quarter ended Jun 30, 2025. The most recent current report (Form 8-K) was filed on Oct 20, 2025 (listing notice, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| RW | Filing | Apr 22, 2026 | — |
| EFFECT | Filing | Nov 14, 2025 | — |
| 15-12G | Deregistration | Nov 13, 2025 | — |
| 25 | Form 25 | Oct 28, 2025 | — |
| 425 | Filing | May 30, 2023 | — |
| 425 | Filing | May 22, 2023 | — |
| EFFECT | Filing | Apr 20, 2023 | — |
| CORRESP | Letter to the SEC | Apr 18, 2023 | — |
| UPLOAD | Letter from the SEC | Apr 6, 2023 | — |
| 425 | Filing | Mar 9, 2023 | — |
| 425 | Filing | Mar 9, 2023 | — |
| 425 | Filing | Mar 6, 2023 | — |
| EFFECT | Filing | Apr 22, 2022 | — |
| CORRESP | Letter to the SEC | Apr 21, 2022 | — |
| UPLOAD | Letter from the SEC | Apr 15, 2022 | — |
| NT 10-K | Filing | Mar 1, 2022 | Dec 31, 2021 |
| CT ORDER | Filing | Nov 4, 2020 | — |
| EFFECT | Filing | Sep 10, 2019 | — |
| CORRESP | Letter to the SEC | Sep 6, 2019 | — |
| UPLOAD | Letter from the SEC | Sep 6, 2019 | — |
| UPLOAD | Letter from the SEC | Dec 20, 2018 | — |
| CORRESP | Letter to the SEC | Dec 3, 2018 | — |
| UPLOAD | Letter from the SEC | Nov 16, 2018 | — |
| CORRESP | Letter to the SEC | Oct 18, 2018 | — |
| CORRESP | Letter to the SEC | Oct 3, 2018 | — |
| UPLOAD | Letter from the SEC | Oct 1, 2018 | — |
| CT ORDER | Filing | Sep 4, 2018 | — |
| CT ORDER | Filing | Apr 30, 2018 | — |
| CT ORDER | Filing | Nov 28, 2017 | — |
| CT ORDER | Filing | May 15, 2017 | — |
| CT ORDER | Filing | Apr 20, 2017 | — |
| EFFECT | Filing | Sep 12, 2016 | — |
| CORRESP | Letter to the SEC | Sep 8, 2016 | — |
| UPLOAD | Letter from the SEC | Sep 6, 2016 | — |
| CORRESP | Letter to the SEC | Sep 6, 2016 | — |
| UPLOAD | Letter from the SEC | Sep 2, 2016 | — |
| CORRESP | Letter to the SEC | Aug 16, 2016 | — |
| CT ORDER | Filing | Aug 16, 2016 | — |
| CORRESP | Letter to the SEC | Aug 10, 2016 | — |
| UPLOAD | Letter from the SEC | Aug 8, 2016 | — |
| UPLOAD | Letter from the SEC | Aug 5, 2016 | — |
| CT ORDER | Filing | Mar 28, 2016 | — |
| EFFECT | Filing | May 6, 2015 | — |
| CT ORDER | Filing | May 6, 2015 | — |
| CERTNAS | Auto-generated paper document | May 6, 2015 | — |
| EFFECT | Filing | May 5, 2015 | — |
| CORRESP | Letter to the SEC | May 1, 2015 | — |
| CORRESP | Letter to the SEC | May 1, 2015 | — |
| 8-A12B | Filing | Apr 30, 2015 | — |
| CORRESP | Letter to the SEC | Apr 27, 2015 | — |
| CORRESP | Letter to the SEC | Apr 22, 2015 | — |
| CORRESP | Letter to the SEC | Apr 17, 2015 | — |
| UPLOAD | Letter from the SEC | Apr 17, 2015 | — |
| CORRESP | Letter to the SEC | Apr 6, 2015 | — |
| UPLOAD | Letter from the SEC | Apr 1, 2015 | — |
| DRSLTR | Filing | Mar 17, 2015 | — |
| DRS/A | Filing | Mar 17, 2015 | — |
| UPLOAD | Letter from the SEC | Mar 4, 2015 | — |
| DRS | Filing | Feb 5, 2015 | — |
| D | Filing | Oct 2, 2014 | — |
Showing 60 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ADAPY (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- Abingdon, Oxfordshire
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1621227
- Former names
- Adaptimmune Ltd (until Mar 17, 2015)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.